Welcome to our dedicated page for QIAGEN N.V. news (Ticker: QGEN), a resource for investors and traders seeking the latest updates and insights on QIAGEN N.V. stock.
QIAGEN N.V. (symbol: QGEN) is a leading global provider of sample-to-insight solutions that transform biological materials into valuable molecular insights. The company's sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. Its assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases from QIAGEN interpret data to report relevant, actionable insights. Automation solutions tie these components together in seamless and cost-effective molecular testing workflows.
QIAGEN serves a diverse customer base of over 500,000 worldwide in sectors such as molecular diagnostics (human healthcare), applied testing (forensics, veterinary testing, and food safety), pharma (pharmaceutical and biotechnology companies), and academia (life sciences research). As of June 30, 2015, the company employed approximately 4,400 people across 35 locations globally. Additional information can be found on their website at http://www.qiagen.com.
QIAGEN's proprietary sample and assay technology enables the extraction, purification, amplification, and interpretation of DNA, RNA, and proteins. The company's revenue is almost evenly split between life sciences and molecular diagnostics applications, with nearly 90% of its revenue derived from consumables and the remaining from instrumentation and related services. The largest portion of QIAGEN's revenue comes from the Americas (over 45% of 2022 sales), followed by EMEA (nearly 35%), and Asia-Pacific (nearly 20%).
Recent achievements include:
- Q1 2024 net sales of $459 million (-5% at actual rates, -5% at constant exchange rates, CER), with a diluted EPS of $0.36 and an adjusted diluted EPS of $0.46. The net sales at CER of $462 million were ahead of the outlook for at least $455 million CER, and the adjusted diluted EPS of $0.47 CER was ahead of the $0.44 CER outlook.
- Strong operating cash flow rose by 85% to $133 million versus Q1 2023.
- The QCI Secondary Analysis software, integrated with QCI Interpret, facilitates high-throughput secondary analysis of clinical next-generation sequencing data.
- Collaborations aimed at creating novel digital PCR assays to improve DNA analysis in forensics and human identification.
- Introduction of the QIAstat-Dx Respiratory Panel Plus for accurate diagnosis of respiratory infections, capable of generating results in about one hour with minimal hands-on time.
- Enhancements to the QIAGEN Clinical Insight Interpret platform, which has processed over 4 million NGS patient test cases for oncology and hereditary diseases worldwide.
- New QIAcuity digital PCR Custom Assay Design Tool for copy number variation analysis, complementing the company's existing assay offerings.
QIAGEN continues to innovate and maintain its leading position in the molecular diagnostics and life sciences industries. The company's ongoing efforts to expand its product offerings and enhance its technologies ensure that it remains a trusted partner for researchers and healthcare providers worldwide.
QIAGEN N.V. (NYSE: QGEN) has surpassed the milestone of three billion biological samples processed with its consumables kits, highlighting its leadership in molecular testing. The company’s sample preparation technology, considered the gold standard, includes over 500 kits and automated systems. QIAGEN continues to innovate with products related to liquid biopsy and microbiome research. Its growth strategy focuses on solidifying its position as a top-three player in sample technologies, contributing to advancements in molecular diagnostics and next-generation sequencing.
QIAGEN has partnered with GT Molecular to launch a comprehensive wastewater testing solution for COVID-19 surveillance in the U.S. and Canada. This innovative workflow utilizes QIAGEN’s sample-preparation techniques with GT Molecular’s digital PCR assays to deliver results in under 2.5 hours, significantly faster than other systems. The assay complies with CDC guidelines and aims to enhance public health responses by quantifying SARS-CoV-2 levels in wastewater. The solution is now available, and the partnership highlights the growing interest in wastewater epidemiology as a tool for monitoring viral spread.
QIAGEN and OncXerna Therapeutics have entered into a master companion diagnostics agreement to develop a next-generation sequencing (NGS) companion diagnostic for OncXerna’s candidate Navicixizumab, aimed at treating ovarian cancer. The agreement includes a non-exclusive license for the Xerna™ TME panel, which uses RNA-based gene expression data to identify suitable patients. The collaboration aims to advance the Xerna™ TME panel towards regulatory approval, enhancing QIAGEN's position in precision medicine diagnostics and potentially benefiting ovarian cancer patients.
QIAGEN (NYSE: QGEN) has received emergency use authorization from the FDA for its QIAreach® SARS-CoV-2 Antigen Test. This rapid test detects active SARS-CoV-2 infections within 2 to 15 minutes and processes approximately 30 samples per hour, boasting a sensitivity of at least 80% and a specificity of 98%. The test is designed for high-volume testing environments, allowing for simultaneous tests of active and past infections with the QIAreach Anti-SARS-CoV-2 Total Test. This innovation is part of QIAGEN's commitment to enhance COVID-19 testing capabilities.
QIAGEN N.V. (NYSE: QGEN) reported strong financial results for Q2 and the first half of 2021, with a 28% increase in net sales to $567.3 million in Q2. Sales for H1 2021 rose 39% to $1.135 billion. Diluted EPS for Q2 was $0.52, up 22% year-over-year, while adjusted EPS reached $0.67. The company noted reduced demand for COVID-19 testing due to rising vaccination rates but remains optimistic about growth in non-COVID product groups and plans a $100 million share repurchase program.
QIAGEN N.V. (NYSE: QGEN) announced preliminary Q2 2021 results and updated its full-year outlook. A conference call is set for July 13, 2021, at 15:00 CET / 9:00 EDT, hosted by CEO Thierry Bernard and CFO Roland Sackers. Stakeholders can join by dialing +1 929 477 0402 (U.S.) or other regional numbers. The company continues to provide Sample to Insight solutions for over 500,000 customers globally across molecular diagnostics and life sciences sectors.
QIAGEN N.V. (NYSE: QGEN) announced strong preliminary results for Q2 2021, with net sales up 28% to $567.3 million, exceeding the expected 20% growth. Adjusted EPS rose about 21% to $0.66-0.67, surpassing projections. Non-COVID product sales surged 52% to $407.6 million, making up 72% of total sales, while COVID-19 product sales declined 17% to $159.7 million due to increased vaccination rates. The company revealed plans for a $100 million share repurchase program to enhance shareholder value, reflecting confidence in future growth.
QIAGEN N.V. (NYSE: QGEN) has announced CE-IVD certification for its NeuMoDx™ HAdV Quant Assay, which identifies and quantifies human adenovirus DNA. This assay is the 15th addition to the NeuMoDx 96 and 288 Molecular Systems, enabling critical testing for immunocompromised patients. Developed with Sentinel Diagnostics, the assay enhances QIAGEN's offerings in transplant health by complementing existing tests for CMV, EBV, and BKV. The NeuMoDx systems provide a comprehensive portfolio, supporting various viral and bacterial pathogen testing.
QIAGEN N.V. (NYSE: QGEN) has launched the Workflow Configurator, a cloud-based tool designed to help life sciences researchers optimize their experiments. This application allows users to select applications, biological materials, and analytes, quickly identifying suitable products from QIAGEN's extensive portfolio. The configurator enhances efficiency by integrating with My QIAGEN and QIAGEN's Web Shop, enabling seamless workflow management. This launch is part of QIAGEN's strategy to digitalize its offerings, emphasizing the importance of digital tools in the life sciences industry.
QIAGEN (NYSE:QGEN) has entered a strategic alliance with Japan’s Sysmex Corporation to enhance cancer companion diagnostics leveraging QIAGEN’s expertise and Sysmex’s Plasma-Safe-SeqS technology. The partnership focuses on collaborating with pharmaceutical companies to develop drug treatments and promote liquid biopsy diagnostics. QIAGEN, a pioneer in precision medicine, boasts an extensive portfolio of FDA-approved diagnostic products and holds master collaboration agreements with over 25 companies. This alliance aims to improve clinical decision-making and patient outcomes in cancer treatment globally.
FAQ
What is the current stock price of QIAGEN N.V. (QGEN)?
What is the market cap of QIAGEN N.V. (QGEN)?
What does QIAGEN N.V. do?
How many employees does QIAGEN N.V. have?
What are QIAGEN's recent financial achievements?
What industries does QIAGEN serve?
What are QIAGEN’s proprietary technologies?
Where can I find more information about QIAGEN?
What are some of QIAGEN's recent innovations?
How is QIAGEN's revenue split?
Which regions contribute most to QIAGEN's revenue?
What is the QIAstat-Dx Respiratory Panel Plus?
